Incyte, a renowned biopharmaceutical company, has acquired Escient Pharmaceuticals, a pioneer in developing small molecule therapeutics for immune disorders. This strategic move expands Incyte’s portfolio with two first-in-class drugs, EP262 and EP547, targeting systemic and neuro-immune conditions.
EP262, a potent antagonist of the MRGPRX2 receptor, holds promise for treating mast cell-mediated diseases such as atopic dermatitis, chronic inducible urticaria, and chronic spontaneous urticaria. Preclinical studies have demonstrated its efficacy in reducing skin lesions and inflammatory markers. In a Phase 1 study, EP262 exhibited safety and tolerability with minimal adverse events.
EP547, an oral MRGPRX4 antagonist, is designed for immune-mediated disorders. Incyte believes these drugs complement its existing portfolio and offer significant potential for addressing unmet medical needs in inflammatory diseases.
“We are thrilled to incorporate EP262 and EP547 into our portfolio,” stated Hervé Hoppenot, Incyte’s Chief Executive Officer. “These innovative therapies align with our strategy of developing first-in-class medicines with transformative potential.”
The acquisition includes Escient’s assets and intellectual property. Incyte will utilize its inflammation and autoimmunity expertise to develop further and commercialize EP262 and EP547, aiming to bring these novel therapies to market by 2029.
